Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 3, Pages 614-619Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1834094
Keywords
Multicentric Castleman's disease; prednisolone; tocilizumab
Categories
Ask authors/readers for more resources
This study found that glucocorticoids have the potential to induce sustained disease control for indolent MCD patients with specific clinical characteristics.
Although anti-interleukin-6 therapy with tocilizumab and siltuximab is recommended for multicentric Castleman's disease (MCD), burdens caused by frequent hospital visits and high drug payments is an issue to be considered. Although glucocorticoid monotherapy might be less effective compared to these agents, substantial proportions of patients can be successfully treated for years. Therefore, we conducted a retrospective analysis of Castleman's disease patients to explore predictors of glucocorticoid responsiveness and revealed that higher hemoglobin and/or lower C-reactive protein levels before starting glucocorticoid monotherapy were associated with lower probability of requirements for second-line treatment among patients initially treated with glucocorticoid. We concluded that glucocorticoids had a potential to induce sustained disease control for indolent MCD patients with specific clinical characteristics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available